Paul W Burridge

List of Publications by Year
in descending order

75 papers	7,153 citations	101543 36 h-index	82547 72 g-index
80 all docs	80 docs citations	80 times ranked	9417 citing authors

#	Article	IF	Citations
1	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. Circulation, 2022, 145, 279-294.	1.6	46
2	Letter by Costantine et al Regarding Article, â€œPravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsiaâ€. Circulation, 2022, 145, e115-e116.	1.6	1
3	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
4	Prime time for doxorubicin-induced cardiotoxicity genetic testing. Pharmacogenomics, 2022, 23, 335-338.	1.3	0
5	A Novel Locus on 6p21.2 for Cancer Treatmentâ€“Induced Cardiac Dysfunction Among Childhood Cancer Survivors. Journal of the National Cancer Institute, 2022, 114, 1109-1116.	6.3	4
6	Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry. Cancer Research, 2021, 81, 2556-2565.	0.9	24
7	Structural and Functional Characterization of a Na _v 1.5-Mitochondrial Couplon. Circulation Research, 2021, 128, 419-432.	4.5	15
8	Cellular model systems to study cardiovascular injury from chemotherapy. Journal of Thrombosis and Thrombolysis, 2021, 51, 890-896.	2.1	8
9	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	33
10	Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity. Pharmacogenomics, 2021, 22, 41-54.	1.3	4
11	An updated protocol for the cost-effective and weekend-free culture of human induced pluripotent stem cells. STAR Protocols, 2021, 2, 100213.	1.2	5
12	Targeting the Microtubule EB1-CLASP2 Complex Modulates Na _V 1.5 at Intercalated Discs. Circulation Research, 2021, 129, 349-365.	4.5	23
13	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell, 2021, 28, 2076-2089.e7.	11.1	36
14	Doxorubicin-Induced Ascension of Resident Cardiac Macrophages. Circulation Research, 2020, 127, 628-630.	4.5	1
15	GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes. Molecular Pharmacology, 2020, 98, 540-547.	2.3	17
16	Lymphoangiocrine signals promote cardiac growth and repair. Nature, 2020, 588, 705-711.	27.8	103
17	Association of GSTM1 null variant with anthracyclineâ€related cardiomyopathy after childhood cancerâ€”A Children's Oncology Group ALTE03N1 report. Cancer, 2020, 126, 4051-4058.	4.1	23
18	Generating a Costâ€Effective, Weekendâ€Free Chemically Defined Human Induced Pluripotent Stem Cell (hiPSC) Culture Medium. Current Protocols in Stem Cell Biology, 2020, 53, e110.	3.0	1

#	Article	IF	Citations
19	Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiological Genomics, 2020, 52, 293-303.	2.3	29
20	Pluripotent Stem Cell Modeling of Anticancer Therapyâ€“Induced Cardiotoxicity. Current Cardiology Reports, 2020, 22, 56.	2.9	2
21	Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. IScience, 2020, 23, 100971.	4.1	7
22	Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity. Journal of Cardiovascular Translational Research, 2020, 13, 377-389.	2.4	11
23	Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. Stem Cell Reports, 2020, 14, 256-270.	4.8	80
24	Use of Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association. Circulation Research, 2019, 125, e75-e92.	4.5	103
25	Genetic Mosaicism in Calmodulinopathy. Circulation Genomic and Precision Medicine, 2019, 12, 375-385.	3.6	33
26	Are These Cardiomyocytes? Protocol Development Reveals Impact of Sample Preparation on the Accuracy of Identifying Cardiomyocytes by Flow Cytometry. Stem Cell Reports, 2019, 12, 395-410.	4.8	14
27	hiPSCs in cardio-oncology: deciphering the genomics. Cardiovascular Research, 2019, 115, 935-948.	3.8	21
28	Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease. Cell Stem Cell, 2019, 24, 203-205.	11.1	5
29	Late onset heart failure after childhood chemotherapy. European Heart Journal, 2019, 40, 798-800.	2.2	18
30	Stage-specific Effects of Bioactive Lipids on Human iPSC Cardiac Differentiation and Cardiomyocyte Proliferation. Scientific Reports, 2018, 8, 6618.	3.3	32
31	Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. Stem Cells, 2018, 36, 265-277.	3.2	111
32	Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. Annual Review of Pharmacology and Toxicology, 2018, 58, 83-103.	9.4	89
33	The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity. Pharmacogenomics, 2018, 19, 79-82.	1.3	10
34	Use of human induced pluripotent stem cellâ€“derived cardiomyocytes to assess drug cardiotoxicity. Nature Protocols, 2018, 13, 3018-3041.	12.0	102
35	Doxorubicin induces caspase-mediated proteolysis of KV7.1. Communications Biology, 2018, 1, 155.	4.4	5
36	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Science Translational Medicine, 2017, 9, .	12.4	297

#	Article	IF	Citations
37	Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-Î² and Cardiac Fibrosis. Circulation, 2017, 136, 664-679.	1.6	64
38	Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease. Microsystems and Nanoengineering, 2017, 3, 16080.	7.0	49
39	Acute CD47 Blockade During Ischemic Myocardial Reperfusion Enhances Phagocytosis-Associated Cardiac Repair. JACC Basic To Translational Science, 2017, 2, 386-397.	4.1	40
40	Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2. Journal of Clinical Investigation, 2017, 127, 1505-1516.	8.2	101
41	Generation and Application of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Cardiac and Vascular Biology, 2017, , 67-106.	0.2	0
42	Human induced pluripotent stem cellâ€“derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine, 2016, 22, 547-556.	30.7	573
43	Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. , 2016, 168, 113-125.		61
44	Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses InÂVitro. Cell Stem Cell, 2016, 19, 311-325.	11.1	131
45	Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. Current Protocols in Human Genetics, 2015, 87, 21.3.1-21.3.15.	3.5	112
46	Derivation of Highly Purified Cardiomyocytes from Human Induced Pluripotent Stem Cells Using Small Molecule-modulated Differentiation and Subsequent Glucose Starvation. Journal of Visualized Experiments, 2015, , .	0.3	68
47	Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. Annual Review of Genetics, 2015, 49, 461-484.	7.6	63
48	Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes. Methods in Molecular Biology, 2015, 1353, 119-130.	0.9	35
49	Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free induction of pluripotency. Scientific Reports, 2015, 5, 8081.	3.3	51
50	Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism. European Heart Journal, 2015, 36, 806-816.	2.2	40
51	Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system. Science Translational Medicine, 2014, 6, 255ra130.	12.4	84
52	Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: A new window into personalized medicine. Progress in Pediatric Cardiology, 2014, 37, 23-27.	0.4	9
53	Human Stem Cells for Modeling Heart Disease and for Drug Discovery. Science Translational Medicine, 2014, 6, 239ps6.	12.4	175
54	High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry. Journal of Visualized Experiments, 2014, , 52010.	0.3	56

#	Article	IF	Citations
55	Induced Pluripotent Stem Cells from Familial Alzheimer's Disease Patients Differentiate into Mature Neurons with Amyloidogenic Properties. Stem Cells and Development, 2014, 23, 2996-3010.	2.1	75
56	Human Induced Pluripotent Stem Cellâ€"Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3â€"Induced Myocarditis and Antiviral Drug Screening Platform. Circulation Research, 2014, 115, 556-566.	4.5	134
57	Chemically defined generation of human cardiomyocytes. Nature Methods, 2014, 11, 855-860.	19.0	1,320
58	A Human Pluripotent Stem Cell Surface N-Glycoproteome Resource Reveals Markers, Extracellular Epitopes, and Drug Targets. Stem Cell Reports, 2014, 3, 185-203.	4.8	73
59	Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes. American Journal of Translational Research (discontinued), 2014, 6, 724-35.	0.0	32
60	MicroRNA-302 Increases Reprogramming Efficiency via Repression of NR2F2. Stem Cells, 2013, 31, 259-268.	3.2	121
61	A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards. Journal of Cardiovascular Translational Research, 2013, 6, 22-30.	2.4	114
62	Highly Efficient Directed Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes. Methods in Molecular Biology, 2013, 997, 149-161.	0.9	35
63	Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cellâ€"Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays. Circulation, 2013, 128, S3-13.	1.6	269
64	Generation of Human iPSCs from Human Peripheral Blood Mononuclear Cells Using Non-integrative Sendai Virus in Chemically Defined Conditions. Methods in Molecular Biology, 2013, 1036, 81-88.	0.9	72
65	Molecular Imaging of Stem Cells: Tracking Survival, Biodistribution, Tumorigenicity, and Immunogenicity. Theranostics, 2012, 2, 335-345.	10.0	107
66	Engraftment of human embryonic stem cell derived cardiomyocytes improves conduction in an arrhythmogenic in vitro model. Journal of Molecular and Cellular Cardiology, 2012, 53, 15-23.	1.9	37
67	Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming. Cell Stem Cell, 2012, 10, 16-28.	11.1	616
68	A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability. PLoS ONE, 2011, 6, e18293.	2.5	363
69	Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology. Proteomics, 2011, 11, 3947-3961.	2.2	20
70	Derivation and characterisation of the human embryonic stem cell lines, NOTT1 and NOTT2. In Vitro Cellular and Developmental Biology - Animal, 2010, 46, 367-375.	1.5	8
71	Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells. International Journal of Developmental Biology, 2010, 54, 965-990.	0.6	29
72	Improved Human Embryonic Stem Cell Embryoid Body Homogeneity and Cardiomyocyte Differentiation from a Novel V-96 Plate Aggregation System Highlights Interline Variability. Stem Cells, 2007, 25, 929-938.	3.2	275

#	Article	IF	Citations
73	Hematopoiesis from Human Embryonic Stem Cells: Overcoming the Immune Barrier in Stem Cell Therapies. Stem Cells, 2006, 24, 815-824.	3.2	36
74	Human embryonic stem cells as a model for nutritional programming: An evaluation. Reproductive Toxicology, 2005, 20, 353-367.	2.9	18
75	A physical map of the mouse genome. Nature, 2002, 418, 743-750.	27.8	316